Search results
Showing 31 to 45 of 163 results for coronary artery disease
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Evidence on the efficacy of bioresorbable stent implantation to treat coronary artery disease is inadequate. Evidence on its safety has...
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.
Totally endoscopic robotically assisted coronary artery bypass grafting (IPG128)
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.
View recommendations for IPG128Show all sections
Sections for IPG128
Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)
Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting. This involves removing the vein under endoscopic guidance through a small cut near the knee (keyhole surgery).
Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.
View recommendations for IPG378Show all sections
Sections for IPG378
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
Transmyocardial laser revascularisation for refractory angina pectoris (IPG301)
Evidence-based recommendations on transmyocardial laser revascularisation for refractory angina pectoris. This involves open heart surgery to drill holes on the heart muscle using a laser beam.
View recommendations for IPG301Show all sections
Sections for IPG301
Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.
View recommendations for IPG377Show all sections
Sections for IPG377
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Angina and coronary heart disease: anti-platelet or anticoagulation (IND132)
This indicator covers the percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM88.
Discontinued Reference number: GID-TA10429
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.